Voyager Therapeutics Inc. ( (VYGR) ) has released its Q1 earnings. Here is a breakdown of the information Voyager Therapeutics Inc. presented to its investors.
Voyager Therapeutics, Inc., a biotechnology company focused on genetic therapies for neurological diseases, has reported its financial results for the first quarter of 2025. The company is advancing its pipeline with programs targeting Alzheimer’s disease, Friedreich’s ataxia, and Parkinson’s disease, among others.
In the first quarter of 2025, Voyager Therapeutics maintained a strong cash position of $295 million, expected to support operations into mid-2027. The company reported a net loss of $31 million, primarily due to decreased collaboration revenue and increased research and development expenses. Voyager continues to advance its tau-targeting programs, with significant progress in its VY1706 and VY7523 therapies for Alzheimer’s disease.
Key highlights include ongoing clinical trials and anticipated investigational new drug submissions for its partnered programs with Neurocrine Biosciences. The company also presented promising data at major conferences, showcasing the potential of its gene therapy and antibody programs to address critical targets in neurological disorders.
Looking forward, Voyager Therapeutics remains committed to advancing its pipeline and maintaining a strong financial position. The company anticipates further clinical developments and data readouts in the coming years, which could enhance its strategic position in the biotechnology sector.